Design of the SILICOFCM study: Effect of sacubitril/valsartan vs lifestyle intervention on functional capacity in patients with hypertrophic cardiomyopathy.

Maria TafelmeierAndrea BaesslerStefan WagnerBernhard UnsoeldAndrej PrevedenFausto BarloccoAlessia TomberliDejana PopovicPaul BrennanGuy A MacGowanArsen RisticLazar VelickiIacopo OlivottoDjordje G JakovljevicLars S Maier

Published in: Clinical cardiology (2020)

The SILICOFCM study will provide novel evidence about the effect of sacubitril/valsartan or lifestyle intervention on functional capacity, clinical phenotype, injury and stretch activation markers, physical activity, and quality of life in patients with nonobstructive HCM.

Keyphrases

hypertrophic cardiomyopathy
physical activity
randomized controlled trial
left ventricular
metabolic syndrome
cardiovascular disease
weight loss
heart failure
ejection fraction